Pharmacogenomics

When a drug or combination of drugs causes different responses in different people, genetic variation is often at play. Pharmacogenomics, through discovery of genetic risk and use of clinical genotyping, aims to reduce trial-and-error approaches to drug prescribing. Read More

Vanderbilt researchers have developed a response score using genetic and clinical information to aid prescribing of the widely used pain medication codeine. Read More

By defining the clinical and genetic factors that predict treatment response, Vanderbilt investigators aim to personalize therapy for a common heart complication in preterm infants. Read More

La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range of diseases, including rare genetic disorders. Read More

Vanderbilt University Medical Center has received a five-year, $12.8 million grant from the federal government to develop better ways to predict how patients will respond to the drugs they’re given. Read More

Preemptive genotyping: It sounds like a surprise attack, and it is. Read More

Vanderbilt faculty and staff are invited to attend Personalized Medicine Day on Friday, May 1, 8 a.m. to 4 p.m. at the Vanderbilt University Student Life Center. Read More

Dan Roden, M.D., assistant vice chancellor for Personalized Medicine, has been appointed to the National Advisory Council for Human Genome Research of the National Institutes of Health (NIH). Read More

With the aid of a two-year, $487,000 National Leadership Grant from the Institute of Museum and Library Services (IMLS), a Vanderbilt research team will develop a reusable model to promote better patient engagement with the health care team through delivery of consumer-friendly pharmacogenetic information. Read More

A research team led by Josh Peterson, M.D., MPH, assistant professor of Biomedical Informatics and Medicine, and John Graves, Ph.D., assistant professor of Preventive Medicine, will study the cost-effectiveness of testing patients’ risk of adverse gene-drug interactions. Read More

The U.S. Centers for Disease Control and Prevention has awarded Vanderbilt researchers a two-year, $1 million grant to Vanderbilt to develop a model for applying genomic testing to drug prescribing in “real-world” settings. Read More